VERCISE DEEP BRAIN STIMULATION (DBS) SYSTEM
Boston Scientific Corp · Decision date Sep 13, 2026
What did the FDA approve?
The FDA's 13 September 2026 approval covers P150031/S084, a labeling-change supplement to Boston Scientific's Vercise Genus deep brain stimulation system. The reported purpose is to update MRI guidelines labeling so that the Vercise Cartesia X and HX 16-contact Directional Leads, 16-contact Lead Extensions, and 8x2-contact Lead Extensions are included in the configurations approved for 1.5T MRI scans. The filing used the normal 180-day track, with the stated reason listed as labeling change affecting indications, instructions, shelf life or tradename.
Because the identifier is a supplement to P150031, it modifies labeling for that existing approval rather than constituting a new approval of the whole system. The statement does not specify the revised warning wording, conditions of scanning, or any clinical data, so safety or effectiveness beyond the listed 1.5T configurations cannot be concluded from this record alone.
The source does not describe the original 2020-era PMA scope in detail. What is absent is the specific labeling text changed, the evidence reviewed, and any separate indication change; only the MRI configuration scope is identified.
FDA approval order statement
approval for MRI guidelines labeling updates to include the Vercise Cartesia X and HX 16-contact Directional Leads, 16-contact Lead Extensions, and 8x2-contact Lead extensions of the Vercise Genus DBS System to the configurations approved for 1.5T MRI scans.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track
- Clinical specialty
- Neurology
- Decision date
- Sep 13, 2026
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P150031/S084
- Regulatory pathway
- PMA supplement
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- Decision code
- APPR
- Decision date
- Sep 13, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stimulator, electrical, implanted, for parkinsonian symptoms.
- Applicant
- Boston Scientific Corp
- Product code
- NHL
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P150031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P150031 · Original PMA
VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM
P150031/S084 received
Application receipt date recorded by FDA.
P150031/S084 · FDA decision
Normal 180 Day Track
P150031/S098 · Related supplement
Vercise Genus DBS Systems; Vercise Gevia DBS Systems
P150031/S100 · Related supplement
Vercise DBS Systems
P150031/S102 · Related supplement
Vercise Deep Brain Stimulation (DBS) Systems
Timeline entries are records held by MedtechLedger for P150031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P150031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Boston Scientific Corp | PMA approval | Dec 8, 2017 | FDA | |
| Boston Scientific Corp | PMA supplement | Sep 22, 2026 | FDA | |
Vercise DBS SystemsP150031/S100 | Boston Scientific Corp | PMA supplement | Oct 15, 2026 | FDA |
Vercise Deep Brain Stimulation (DBS) SystemsP150031/S102 | Boston Scientific Corp | PMA supplement | Oct 30, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corp
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 25155 Rye Canyon Loop, Valencia, CA, 91355
Sources and methodology
- Original FDA record: P150031/S084
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

